A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study

被引：0
|
作者：
Prebet, Thomas [1 ,2 ]
Delaunay, Jacques [3 ]
Wattel, Eric [4 ]
Braun, Thorsten [5 ]
Cony-Makhoul, Pascale [6 ]
Dimicoli, Sophie [7 ]
Wickenhauser, Stefan [8 ]
Lejeune, Julie [9 ]
Chevret, Sylvie [10 ]
Chermat, Fatiha [11 ]
Fenaux, Pierre [2 ,12 ,13 ]
Vey, Norbert [14 ]
机构：
[1] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA
[2] Grp Francophone Myelodysplasies, Paris, France
[3] Nantes Univ Hosp, Dept Hematol, Nantes, France
[4] Univ Lyon 1, F-69365 Lyon, France
[5] CHU Avicenne, Hematol Clin, Bobigny, France
[6] Ctr Hosp Annecy Genevois, Dept Hematol, Metz, France
[7] CHU Bordeaux, Serv Hematol, Pessac, France
[8] CH Nimes, Nimes, France
[9] Hop St Louis, AP HP, Paris, France
[10] Stat St Louis Hosp, Paris, France
[11] Hop St Louis, GFM, Paris, France
[12] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France
[13] Univ Paris 08, Hop Avicenne, Serv Hematol Clin, Bobigny, France
[14] Inst J Paoli I Calmettes, Hematol, F-13009 Marseille, France
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents
    Garcia-Manero, Guillermo
    Luger, Selina
    Venugopal, Parameswaran
    Maness, Lori J.
    Wetzler, Meir
    Altman, Jessica
    Claxton, David F.
    Strickland, Stephen
    Faderl, Stefan
    Chiao, Judy
    Kantarjian, Hagop M.
    BLOOD, 2009, 114 (22) : 698 - 699
  • [22] Omacetaxine mepesuccinate for patients with higher-risk MDS and CMML after failure of hypomethylating agents: A phase II clinical trial.
    Sanchez-Petitto, Gabriela
    Garcia-Manero, Guillermo
    Short, Nicholas James
    Naqvi, Kiran
    Andreeff, Michael
    Takahashi, Koichi
    Kornblau, Steven
    Bose, Prithviraj
    Estrov, Zeev
    Konopleva, Marina
    Patel, Ami
    Islam, Rabiul
    Alvarado, Yesid
    Dinardo, Courtney Denton
    Kantarjian, Hagop M.
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] AZACITIDINE (AZA) COMBINED WITH IDARUBICIN (IDA) IN HIGHER RISK MDS (HRMDS) - RESULTS OF A PHASE I/II STUDY BY THE GFM
    Sebert, M.
    Ades, L.
    Stamatoullas, A.
    Braun, T.
    Delaunay, J.
    de Renzis, B.
    Jeddi, R.
    Meddeb, B.
    Berger, M. Hunault
    Samey, B.
    Chermat, F.
    Chaffaut, C.
    Chevert, S.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2015, 39 : S63 - S63
  • [24] Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)
    Garcia-Manero, Guillermo
    Scott, Bart L.
    Kishtagari, Ashwin
    Sanikommu, Srinivasa R.
    Al-Kali, Aref
    Lee, Je-Hwan
    Burgues, Juan M. Bergua
    Diez-Campelo, Maria
    Erba, Harry P.
    Garcia-Hernandez, Carmen
    Santillana, Guillermo Sanz
    O'Connell, Casey
    Jang, Jun-Ho
    Shin, Dong-Yeop
    Sayar, Hamid
    Rao, Mayank
    Schwartz, Richard S.
    An, Grace
    Jin, Feng
    Forgie, Alison J.
    Tsiatis, Athanasios C.
    Altman, Jessica K.
    CANCER RESEARCH, 2024, 84 (07)
  • [25] Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
    Chien, Kelly S.
    Borthakur, Gautam M.
    Naqvi, Kiran
    Daver, Naval G.
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Jabbour, Elias
    Andreeff, Michael
    Alvarado, Yesid
    Bose, Prithviraj
    Jain, Nitin
    Sheppard, Kimberly
    Klingner-Winton, Cheri
    Pierce, Sherry A.
    Dong, Xiao Qin
    Soltysiak, Kelly
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2019, 134
  • [26] Phase II Pilot Study of Oral Dasatinib in Subjects with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed Conventional Therapy
    Duong, Vu H.
    Jaglal, Michael V.
    Zhang, Ling
    Kale, Vishakha
    Lancet, Jeffrey E.
    Komrokji, Rami S.
    List, Alan F.
    BLOOD, 2011, 118 (21) : 752 - 753
  • [27] Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
    Garcia-Manero, Guillermo
    Jonasova, Anna
    Luger, Selina M.
    Al-Kali, Aref
    Valcarcel, David
    Warlick, Erica D.
    Jedrzejczak, Wieslaw W.
    Diez-Campelo, Maria
    Zbyszewski, Patrick S.
    Cavanaugh, Christopher
    Woodman, Richard C.
    Fruchtman, Steven M.
    Takahashi, Koichi
    BLOOD, 2019, 134
  • [28] A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure
    Nazha, Aziz
    Mukherjee, Sudipto
    Advani, Anjali S.
    Waldron, Madeline
    Siebenaller, Caitlin
    Thomas, Jenna
    Parsons, Eric
    Carraway, Hetty E.
    Gerds, Aaron T.
    Patel, Bhumika J.
    Sekeres, Mikkael A.
    BLOOD, 2020, 136
  • [29] A Phase I Study of the Myeloid Cell Leukemia 1 (MCL1) Inhibitor Tapotoclax (AMG 176) in Patients With Myelodysplastic Syndromes After Hypomethylating Agent (HMA) Failure
    Chien, Kelly
    Rodriguez-Sevilla, Juan Jose
    Alvarado, Yesid
    Montalban-Bravo, Guillermo
    Hammond, Danielle E.
    Swaminathan, Mahesh
    Bazinet, Alexandre
    Kimberley, Jacqueline
    Bodden, Kristy
    Schneider, Heather
    Huang, Xuelin
    Jabbour, Elias J.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S399 - S399
  • [30] Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy
    Duong, Vu H.
    Jaglal, Michael V.
    Zhang, Ling
    Kale, Vishakha
    Lancet, Jeffrey E.
    Komrokji, Rami S.
    List, Alan F.
    LEUKEMIA RESEARCH, 2013, 37 (03) : 300 - 304
12345